A Randomized, Double-blind (Sponsor-unblinded), Placebo-controlled, Single-ascending-dose Study in Healthy Volunteers and a Double-blind (Sponsor-unblinded), Placebo-controlled, Multiple-ascending-dose Study in Patients With Parkinson's Disease to Evaluate the Safety, Tolerability, and PK/PD of LY3962681
Latest Information Update: 21 Aug 2025
At a glance
- Drugs LY 3962681 (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Acronyms PROSPECT
- Sponsors Prevail Therapeutics
Most Recent Events
- 23 Sep 2024 Status changed from not yet recruiting to recruiting.
- 27 Aug 2024 New trial record